Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1956 Nov 3;2(5000):1023–1027. doi: 10.1136/bmj.2.5000.1023

Dextran Sulphate: Use as an Anticoagulant, and Action in Lowering Serum Cholesterol

H Cohen, G R Tudhope
PMCID: PMC2035700  PMID: 13364378

Full text

PDF
1023

Images in this article

1027Fig. 1
on p.1027
1027Fig. 2
on p.1027

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACKERMAN R. F., ZILVERSMIT D. B. The heparin-like action of treburon in abolishing alimentary lipemia in normal individuals. Circulation. 1953 Apr;7(4):581–584. doi: 10.1161/01.cir.7.4.581. [DOI] [PubMed] [Google Scholar]
  2. BASU D. P., STEWART C. P. The effect of heparin on the plasma cholesterol. Edinb Med J. 1950 Dec;57(12):596–599. [PMC free article] [PubMed] [Google Scholar]
  3. BLOCK W. J., BARKER N. W., MANN F. D. Effect of small doses of heparin in increasing the translucence of plasma during alimentary lipemia; studies in normal persons and patients having arteriosclerosis. Circulation. 1951 Nov;4(5):674–678. doi: 10.1161/01.cir.4.5.674. [DOI] [PubMed] [Google Scholar]
  4. CHANDLER H. L., LAWRY E. Y., POTEE K. G., MANN G. V. Spontaneous and induced variations in serum lipoproteins. Circulation. 1953 Nov;8(5):723–731. doi: 10.1161/01.cir.8.5.723. [DOI] [PubMed] [Google Scholar]
  5. DUFF I. F., LINMAN J. W., BIRCH R. The administration of heparin. Surg Gynecol Obstet. 1951 Sep;93(3):343–362. [PubMed] [Google Scholar]
  6. GRAHAM D. M., LYON T. P., GOFMAN J. W., JONES H. B., YANKLEY A., SIMONTON J., WHITE S. Blood lipids and human atherosclerosis. II. The influence of heparin upon lipoprotein metabolism. Circulation. 1951 Nov;4(5):666–673. doi: 10.1161/01.cir.4.5.666. [DOI] [PubMed] [Google Scholar]
  7. HERZSTEIN J., WANG C. I., ALDERSBERG D. Effect of heparin on plasma lipid partition in man: studies in normal persons and in patients with coronary atherosclerosis, nephrosis and primary hyperlipemia. Ann Intern Med. 1954 Feb;40(2):290–305. doi: 10.7326/0003-4819-40-2-290. [DOI] [PubMed] [Google Scholar]
  8. HIRSCHBOECK J. S., MADISON F. W. A comparison of the anticoagulant properties of a polyhexuronic acid ester with sodium heparin. J Lab Clin Med. 1950 Nov;36(5):836–836. [PubMed] [Google Scholar]
  9. HIRSCHBOECK J. S., MADISON F. W., PISCIOTTA A. V. Alopecia and other toxic effects of heparin and synthetic heparinoids. Am J Med Sci. 1954 Mar;227(3):279–282. [PubMed] [Google Scholar]
  10. HOLLISTER L. E., KANTER S. L. Essential hyperlipemia treated with heparin and with chlorpromazine. Gastroenterology. 1955 Dec;29(6):1069–1076. [PubMed] [Google Scholar]
  11. Hahn P. F. ABOLISHMENT OF ALIMENTARY LIPEMIA FOLLOWING INJECTION OF HEPARIN. Science. 1943 Jul 2;98(2531):19–20. doi: 10.1126/science.98.2531.19. [DOI] [PubMed] [Google Scholar]
  12. MANGIERI C. N., ENGELBERG R., RANDALL L. O. The heparin-like activity of a new anticoagulant, treburon. J Pharmacol Exp Ther. 1951 Jul;102(3):156–164. [PubMed] [Google Scholar]
  13. OLIVER M. F., BOYD G. S. The clearing by heparin of alimentary lipaemia in coronary artery disease. Clin Sci. 1953;12(3):293–298. [PubMed] [Google Scholar]
  14. OPDYKE D. F., ROSENBERG A., SILBER R., OTT W. H., SIEGEL H. Effect of chronic injection of a heparin complex on aortic atherosclerosis in cholesterol-fed chickens. J Lab Clin Med. 1955 Feb;45(2):270–273. [PubMed] [Google Scholar]
  15. RICKETTS C. R. Dextran sulphate--a synthetic analogue of heparin. Biochem J. 1952 Apr;51(1):129–133. doi: 10.1042/bj0510129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. RICKETTS C. R., WALTON K. W., VAN LEUVEN B. D., BIRBECK A., BROWN A., KENNEDY A. C., BURT C. C. Therapeutic trial of the synthetic heparin analogue dextran sulphate. Lancet. 1953 Nov 14;265(6794):1004–1010. doi: 10.1016/s0140-6736(53)91306-3. [DOI] [PubMed] [Google Scholar]
  17. ROSENBERG I. N. Serum lipids studied by electrophoresis on paper. Proc Soc Exp Biol Med. 1952 Aug-Sep;80(4):751–756. doi: 10.3181/00379727-80-19752. [DOI] [PubMed] [Google Scholar]
  18. SCHOLZ D. A., BARKER N. W. Preliminary studies of a new anticoagulant drug. Proc Staff Meet Mayo Clin. 1952 Aug 13;27(17):332–335. [PubMed] [Google Scholar]
  19. SOFFER A., MURRAY M. Prolonged observations of the cardiovascular status in essential hyperlipemia; with special reference to serum lipid response to heparin. Circulation. 1954 Aug;10(2):255–264. doi: 10.1161/01.cir.10.2.255. [DOI] [PubMed] [Google Scholar]
  20. SORENSON C. W., WRIGHT I. S. A synthetic anticoagulant: a polysulfuric acid ester of polyanhydromannuronic acid (paritol); experience with its use in man. Circulation. 1950 Nov;2(5):658–667. doi: 10.1161/01.cir.2.5.658. [DOI] [PubMed] [Google Scholar]
  21. UTZ J. P., MANN F. D., BARKER N. W. Clearing of lipemic plasma by heparin; duration of effect and other studies. Proc Staff Meet Mayo Clin. 1953 Sep 23;28(19):531–536. [PubMed] [Google Scholar]
  22. WALTON K. Experiments with dextran sulphate as an anticoagulant. Proc R Soc Med. 1951 Jul;44(7):563–564. [PMC free article] [PubMed] [Google Scholar]
  23. ZINN W. J., FIELD J. B., GRIFFITH G. C. Effect of heparin and treburon in postprandial hyperlipemia. Proc Soc Exp Biol Med. 1952 Jun;80(2):276–278. doi: 10.3181/00379727-80-19594. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES